Literature DB >> 25892683

Profiles of cancer stem cell subpopulations in cholangiocarcinomas.

Vincenzo Cardinale1, Anastasia Renzi2, Guido Carpino3, Alessia Torrice1, Maria C Bragazzi1, Felice Giuliante4, Agostino M DeRose4, Alice Fraveto1, Paolo Onori2, Chiara Napoletano5, Antonio Franchitto6, Alfredo Cantafora1, GianLuca Grazi7, Nicola Caporaso8, Giuseppe D'Argenio8, Gianfranco Alpini9, Lola M Reid10, Eugenio Gaudio2, Domenico Alvaro11.   

Abstract

Cholangiocarcinomas (CCAs) comprise a mucin-secreting form, intrahepatic or perihilar, and a mixed form located peripherally. We characterized cancer stem cells (CSCs) in CCA subtypes and evaluated their cancerogenic potential. CSC markers were investigated in 25 human CCAs in primary cultures and established cell lines. Tumorigenic potential was evaluated in vitro or in xenografted mice after s.c. or intrahepatic injection in normal and cirrhotic (carbon tetrachloride-induced) mice. CSCs comprised more than 30% of the tumor mass. Although the CSC profile was similar between mucin-intrahepatic and mucin-perihilar subtypes, CD13(+) CSCs characterized mixed-intrahepatic, whereas LGR5(+) characterized mucin-CCA subtypes. Many neoplastic cells expressed epithelial-mesenchymal transition markers and coexpressed mesenchymal and epithelial markers. In primary cultures, epithelial-mesenchymal transition markers, mesenchymal markers (vimentin, CD90), and CD13 largely predominated over epithelial markers (CD133, EpCAM, and LGR5). In vitro, CSCs expressing epithelial markers formed a higher number of spheroids than CD13(+) or CD90(+) CSCs. In s.c. tumor xenografts, tumors dominated by stromal markers were formed primarily by CD90(+) and CD13(+) cells. By contrast, in intrahepatic xenografts in cirrhotic livers, tumors were dominated by epithelial traits reproducing the original human CCAs. In conclusion, CSCs were rich in human CCAs, implicating CCAs as stem cell-based diseases. CSC subpopulations generate different types of cancers depending on the microenvironment. Remarkably, CSCs reproduce the original human CCAs when injected into cirrhotic livers.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25892683      PMCID: PMC4450332          DOI: 10.1016/j.ajpath.2015.02.010

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages.

Authors:  Guido Carpino; Vincenzo Cardinale; Paolo Onori; Antonio Franchitto; Pasquale Bartolomeo Berloco; Massimo Rossi; Yunfang Wang; Rossella Semeraro; Maurizio Anceschi; Roberto Brunelli; Domenico Alvaro; Lola M Reid; Eugenio Gaudio
Journal:  J Anat       Date:  2011-12-05       Impact factor: 2.610

Review 2.  Stem cells and their implications for colorectal cancer.

Authors:  Sebastian S Zeki; Trevor A Graham; Nicholas A Wright
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

3.  CD13 is a therapeutic target in human liver cancer stem cells.

Authors:  Naotsugu Haraguchi; Hideshi Ishii; Koshi Mimori; Fumiaki Tanaka; Masahisa Ohkuma; Ho Min Kim; Hirofumi Akita; Daisuke Takiuchi; Hisanori Hatano; Hiroaki Nagano; Graham F Barnard; Yuichiro Doki; Masaki Mori
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

Review 4.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

5.  Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.

Authors:  W Song; H Li; K Tao; R Li; Z Song; Q Zhao; F Zhang; K Dou
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

Review 6.  CD133: molecule of the moment.

Authors:  D Mizrak; M Brittan; M R Alison
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 7.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

Review 8.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

9.  Human hepatic stem cells from fetal and postnatal donors.

Authors:  Eva Schmelzer; Lili Zhang; Andrew Bruce; Eliane Wauthier; John Ludlow; Hsin-lei Yao; Nicholas Moss; Alaa Melhem; Randall McClelland; William Turner; Michael Kulik; Sonya Sherwood; Tommi Tallheden; Nancy Cheng; Mark E Furth; Lola M Reid
Journal:  J Exp Med       Date:  2007-07-30       Impact factor: 14.307

10.  Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray.

Authors:  T Nitta; T Mitsuhashi; Y Hatanaka; M Miyamoto; K Oba; T Tsuchikawa; Y Suzuki; K C Hatanaka; S Hirano; Y Matsuno
Journal:  Br J Cancer       Date:  2014-07-31       Impact factor: 7.640

View more
  40 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.

Authors:  Chiara Raggi; Margherita Correnti; Antonio Sica; Jesper B Andersen; Vincenzo Cardinale; Domenico Alvaro; Giovanna Chiorino; Elisa Forti; Shannon Glaser; Gianfranco Alpini; Annarita Destro; Francesca Sozio; Luca Di Tommaso; Massimo Roncalli; Jesus M Banales; Cédric Coulouarn; Luis Bujanda; Guido Torzilli; Pietro Invernizzi
Journal:  J Hepatol       Date:  2016-09-01       Impact factor: 25.083

3.  3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma.

Authors:  Onanong Buhome; Molin Wongwattanakul; Jureerut Daduang; Temduang Limpaiboon
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

4.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

5.  Identification of a Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma.

Authors:  Colm J O'Rourke; Matthias S Matter; Chirag Nepal; Rui Caetano-Oliveira; Phuongnga T Ton; Valentina M Factor; Jesper B Andersen
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.298

6.  Therapeutic effects of dexamethasone-loaded hyaluronan nanogels in the experimental cholestasis.

Authors:  Sabina Di Matteo; Chiara Di Meo; Guido Carpino; Nicole Zoratto; Vincenzo Cardinale; Lorenzo Nevi; Diletta Overi; Daniele Costantini; Claudio Pinto; Elita Montanari; Marco Marzioni; Luca Maroni; Antonio Benedetti; Marco Viola; Tommasina Coviello; Pietro Matricardi; Eugenio Gaudio; Domenico Alvaro
Journal:  Drug Deliv Transl Res       Date:  2022-02-28       Impact factor: 5.671

Review 7.  Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.

Authors:  Leonardo Baiocchi; Keisaku Sato; Burcin Ekser; Lindsey Kennedy; Heather Francis; Ludovica Ceci; Ilaria Lenci; Domenico Alvaro; Antonio Franchitto; Paolo Onori; Eugenio Gaudio; Chaodong Wu; Sanjukta Chakraborty; Shannon Glaser; Gianfranco Alpini
Journal:  Expert Opin Investig Drugs       Date:  2020-12-08       Impact factor: 6.206

8.  Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study.

Authors:  Lu Cao; Prashanth Prithviraj; Ritu Shrestha; Revati Sharma; Matthew Anaka; Kim R Bridle; George Kannourakis; Darrell H G Crawford; Aparna Jayachandran
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

9.  DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.

Authors:  Lorenzo Nevi; Sabina Di Matteo; Guido Carpino; Ilaria Grazia Zizzari; Safarikia Samira; Valeria Ambrosino; Daniele Costantini; Diletta Overi; Antonella Giancotti; Marco Monti; Daniela Bosco; Valerio De Peppo; Andrea Oddi; Agostino Maria De Rose; Maria Consiglia Bragazzi; Jessica Faccioli; Sara Massironi; Gian Luca Grazi; Pierluigi Benedetti Panici; Paquale Bartomeo Berloco; Felice Giuliante; Vincenzo Cardinale; Pietro Invernizzi; Giuseppina Caretti; Eugenio Gaudio; Domenico Alvaro
Journal:  Hepatology       Date:  2021-01       Impact factor: 17.425

10.  Doublecortin-Like Kinase Protein 1 in Cholangiocarcinoma: Is This the Biomarker and Target We Have Been Looking For?

Authors:  Vik Meadows; Heather Francis
Journal:  Hepatology       Date:  2021-01       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.